Atabak Mokari - Jun 1, 2023 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Signature
/s/ Joseph Douglas Lyon, as attorney-in-fact for Atabak Mokari
Stock symbol
CORT
Transactions as of
Jun 1, 2023
Transactions value $
$37,923
Form type
4
Date filed
6/5/2023, 07:03 PM
Previous filing
Mar 3, 2023
Next filing
Sep 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CORT Common Stock Award $37.9K +1.65K +40.21% $22.97 5.76K Jun 1, 2023 Direct F1, F2, F3
transaction CORT Common Stock Award $0 +1.65K +28.68% $0.00 7.41K Jun 1, 2023 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on June 1, 2023.
F2 In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
F3 Includes 793 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, and 1,260 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F4 Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.